Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
Phase 4
Completed
- Conditions
- Healthy
- Registration Number
- NCT00581035
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 712
Inclusion Criteria
- Healthy infants aged 6 to 9 weeks
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The pneumococcal and meningococcal responses achieved after the infant series 7 months
- Secondary Outcome Measures
Name Time Method The pneumococcal and meningococcal responses achieved after the toddler dose 13 months